Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4517683
Author(s) Navarini, Alexander A.; Trüeb, Ralph M.
Author(s) at UniBasel Navarini, Alexander
Year 2010
Title 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease
Journal Archives of dermatology
Volume 146
Number 5
Pages / Article-Number 517-20
Mesh terms Adalimumab; Adult; Anti-Inflammatory Agents, pharmacology, therapeutic use; Antibodies, Monoclonal, pharmacology, therapeutic use; Antibodies, Monoclonal, Humanized; Cellulitis, drug therapy, physiopathology; Drug Delivery Systems; Humans; Inflammation, drug therapy, etiology, physiopathology; Male; Scalp, pathology; Secondary Prevention; Tumor Necrosis Factor-alpha, antagonists & inhibitors
Abstract Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disease of scalp hair follicles manifesting as multiple painful nodules and abscesses that interconnect via sinus tracts. The disease tends to run a progressive course that eventually results in scarring alopecia. The condition is thought to represent a follicular occlusion disorder. Sebaceous and keratinous material within dilated pilosebaceous units accumulates until follicles burst, with subsequent neutrophilic inflammatory reaction and abscess formation. Treatment remains unsatisfactory. While oral antibiotics, intralesional corticosteroids, isotretinoin, or dapsone are insufficient, in this case series the inflammation responsible for scarifying tissue destruction was directly targeted by means of the tumor necrosis factor antagonist adalimumab. Observation Clinical signs of inflammation as well as burden of disease measured by a score of 0 to 10 (P < .04) was reduced rapidly by adalimumab. Histopathologic characteristics demonstrated marked improvement of inflammation, despite persistence of underlying structural disease. Relapse was observed following discontinuation of adalimumab.; Adalimumab is effective for treatment of DCS. Relapse on discontinuation of therapy can be expected depending on persisting structural disease. Continuous treatment or combined surgical resection of involved areas could be necessary for definitive resolution of disease.
Publisher American Medical Association
ISSN/ISBN 1538-3652
URL https://doi.org/10.5167/uzh-43105
edoc-URL https://edoc.unibas.ch/76814/
Full Text on edoc No
Digital Object Identifier DOI 10.1001/archdermatol.2010.16
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/20231491
ISI-Number WOS:000277773100009
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.344 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
16/04/2024